| LDR | | | 00000cam a22000004 4500 |
| 001 | | | MAP20260013091 |
| 003 | | | MAP |
| 005 | | | 20260424142201.0 |
| 008 | | | 260424s2026 usa|||| ||| ||eng d |
| 040 | | | $aMAP$bspa$dMAP |
| 084 | | | $a921.8 |
| 110 | 2 | | $0MAPA20080442569$aMcKinsey & Company |
| 245 | 1 | 0 | $aShaping the future of Japan's pharmaceutical operations$cby Orlando Ramirez Cárdenas...[et al.] |
| 260 | | | $aNew York$b McKinsey & Company $c2026 |
| 300 | | | $a38 p. |
| 505 | 0 | | $aExecutive summary: The evolution of Japan's pharmaceutical industry -- The evolution of Japan's pharmaceutical industry: Triumphs and trials -- Trends likely to impact the operations landscape -- Themes for the future of Japanese pharmaceutical operations |
| 520 | | | $aThe report analyzes the current and future state of Japan's pharmaceutical operations in the context of global disruption, regulatory pressure, and technological change. It examines structural challenges such as pricing reforms, demographic shifts, and supply-chain vulnerabilities while highlighting opportunities from digitalization, artificial intelligence, and advanced manufacturing. The study outlines strategic priorities including zero-error quality systems, low-touch automation, modular and continuous manufacturing, and expanded use of CDMOs. Sustainability and resilience are positioned as core operational imperatives. Overall, the document provides a strategic roadmap for maintaining Japan's global leadership in pharmaceutical operations |
| 650 | | 4 | $0MAPA20080606633$aIndustria farmacéutica |
| 650 | | 4 | $0MAPA20080606091$aEstrategia empresarial |
| 650 | | 4 | $0MAPA20170006503$aTransformación digital |
| 650 | | 4 | $0MAPA20080611200$aInteligencia artificial |
| 650 | | 4 | $0MAPA20080568009$aAutomatización |
| 650 | | 4 | $0MAPA20080570736$aSostenibilidad |
| 651 | | 1 | $0MAPA20080650919$aJapón |
| 700 | 1 | | $0MAPA20260007854$aRamirez Cárdenas, Orlando |
